AbstractOsteoarthritis is a high prevalent joint degenerative disease for which therapeutic treatments are limited or invasive. Cellular therapy based on mesenchymal stem cells is therefore seen as a promising approach for this disease. This research project works with equine mesenchymal stem cells harvested in muscle, an easy access site, with a minimally invasive process.
As curcumin is described to improve the osteoarthritis pathology by decreasing the pain and the stiffness of the joint, the goal of this project was to study the combination of both muscle-derived mesenchymal stem cells (mdMSCs) and a hydrosoluble form of curcumin called NDS27.
We have first developed an in vitro model of osteoarthritis disease in order to evaluate the potential clinical effect of this innovative product. This model is focus on cartilage (ex vivo explant) and its response in pro-inflammatory (TNF-a and IL-1β) culture conditions.
Then, as regenerative potential of MSCs is mainly conferred by paracrine function, we have characterized the secretome of mdMSCs in this in vitro model of OA (explant of cartilage with TNF-a and IL-1β). Mass spectrometry analyses identified several actors secreted by mdMSCs. According to the dual function of these secreted proteins, implicated both in catabolic and anabolic cartilage functions, we performed functional tests consisting of studying the effect of mdMSCs cultured with explants of cartilage in pro-inflammatory model. Results showed that mdMSCs decreased the glycosaminoglycan release from plugs of cartilage in this model, supporting the anti-catabolic effect of mdMSCs in these conditions, potentially explained by the increase of secreted decorin and the decreased abundance and activity of MMP3.
Finally, we have demonstrated that NDS27 is able to penetrate into mdMSCs and localizes into mitochondria, at least partially. Optimizations between conditions leading to maximal incorporation of NDS27, regenerative properties and constraints of industrial partner (to fit with good manufacturing practice) must now be done.
|Date of Award||2021|
|Supervisor||Patricia Renard (Supervisor), Didier Serteyn (Co-Supervisor), Florence Debacq-Chainiaux (President), Fanny Hontoir (Jury), Véronique Delcenserie (Jury), René Van Weeren (Jury), Basile Stamatopoulos (Jury), Alexandra Salciccia (Jury) & Olivier Malaise (Jury)|
- Mesenchymal stem cells